灯盏细辛对血瘀型急性脑梗死VEGF、sICAM-1的影响
|
摘要
急性脑梗死(Acute Cerebral Infarction,ACI)是内科常见的急危重症之一,急性脑梗死的病理基础多数以动脉粥样硬化为主,约占80%左右,阻塞血管引起相应供血区脑组织缺血缺氧,形成缺血中心坏死区和缺血半暗带。及时改善缺血半暗带区的血液供应,是缩小梗塞面积的关键所在。同时,如何减轻炎症反应已成为临床上治疗缺血性脑血管疾病的重要措施之一。
急性脑梗死属于祖国医学“中风”病范畴,其临床表现,大体与现代医学中的急性脑血管病相似。从《内经》开始,后世医家特别强调了瘀血在中风发病中的重要地位。本文认为中风发病的病机核心为气血逆乱,其病变关键为血瘀,而活血化瘀法是治疗中风病的根本大法。本课题在既往相关的研究基础上,进一步探讨血瘀证型急性脑梗死患者的血清VEGF、sICAM-1在治疗前后的变化情况,观察灯盏细辛注射液对于血瘀证型急性脑梗死VEGF、sICAM-1的影响,为临床治疗提供理论的依据。
目的:观察灯盏细辛注射液对于血瘀证型急性脑梗死患者的血管内皮生长因子、可溶性细胞间黏附分子-1、血瘀证积分、神经功能缺损症状的影响,探讨急性脑梗死(ACI)血瘀证与VEGF、sICAM-1的关系,分析灯盏细辛治疗ACI的作用机制,探索脑梗死急性期有效的中医药治疗,为临床治疗提供理论的依据。
方法:将符合选择标准的60例ACI患者随机分为治疗组(A组)和对照组(B组),并设立健康老年人30例为正常对照组(C组),观察病例,分为治疗组(A组)和对照组(B组),各组患者的年龄、性别、既往病史等经统计学处理无显著性差异,具有可比性,A组给予静脉滴注灯盏细辛,B组给予速避凝皮下注射;治疗前后分别检测VEGF、sICAM-1,并对患者的血瘀证积分、神经功能缺损积分等分别做出评定。
结果:1.两组之间的疗效比较,治疗组明显优于对照组(P＜0.05=;2.治疗后两组ACI患者血清VEGF、sICAM-1的含量较治疗前均有显著性改善P＜0.01,但治疗组在治疗后VEGF增高较对照组更为明显P＜0.01;治疗组在治疗后sICAM-1的含量与对照组比较P＞0.05;3.血瘀证积分均较治疗前有显著性改善P＜0.01,但治疗组较对照组改善明显P＜0.05;4.ACI患者血瘀证病情的轻重与sICAM-1含量存在显著正相关r=0.901,P＜0.01;与VEGF呈显著负相关r=-0.788,P＜0.01。
结论:血清VEGF、sICAM-1与ACI血瘀证密切相关;灯盏细辛能改善ACI患者的脑血液循环,减轻脑组织缺血性损伤,是脑梗死急性期安全有效的药物。
Acute cerebral infarction, which is abbreviating ACI, is one of the severe cases in internal medicine. The major pathological basis of ACI is atherosclerosis, which take 80 percents. The angiemphraxis caused ischemic and anoxemia in the corresponding blood supply brain tissue. This formed centre zone of necrosis and ischemia semidarkness lane. Thus to improve the blood supply in the ischemia semidarkness lane is the key point in decreasing the infarct size. At the same time, how to lighten the inflammatory reaction is already one of the important steps in clinical treatment on ischemic cerebrovascular disease. ACI belongs to the stroke in traditional Chinese medicine. ACI is similar to acute cerebrovascular disease in modern medicine. From the endo-meridians on, a large quantity of physicians emphasize the important position of stagnant blood in the pathogenesis of stroke.
This article takes it for granted that the core pathogenesis of the stroke is disharmonizing Qi and blood. The key point of the pathological changes is blood stasis. Thus the treatment method of activating blood circulation to dissipate blood stasis is the basic ones in treating the stroke. This study is based on the former investigation results and to move forward a single step for the variation rule of vascular endothelial growth factor (VEGF) and soluble intercellular adhesion molecule-1 (sICAM-1), in the patients of ACI with the syndrome of blood stasis. Then we observed the affection on VEGF and sICAM-1 in patients of ACI with the syndrome of blood stasis. All the results could provide guideline for clinical treatment on patients with ACI.
Objective: To investigate the changes of Vascular Endothelial Growth Factor (VEGF), Soluble Intercellular Adhesion Molecule-1 (sICAM-1), symptom of neurologic impairment in patients with Acute Cerebral Infarction (ACI) of TCM syndrome of blood stasis with erigeron injection. To analyze the mechanism of erigeron injection on ACI, which provides the indexes for clinical treatment of ACI.
Methods : According to the diagnosis standards and Chinese symptom standards, 60 patients with ACI were randomly divided into treated group (A group) and control group (B group), 30 cases of healthy elders were taken as normal control group (C group).The age, gender and integral of past diseases of all groups had no significant difference by statistic treatment. Patients of A group were treated with erigeron injection through intravenous drip, and the patients in B group used Fraxiparine by subcutaneous injection. The levels of blood serum VEGF, sICAM-1 were respectively measured before and after 14 days' treatment by enzyme- linked immunospecific assay and integral of syndrome of blood stasis and neurologic impairment were measured simultaneously.
Results: 1. Compared the two groups' curative effect, the treatment group obviously surpassed control group (P<0. 05 = . 2. After treatment, the level of blood serums of VEGF, sICAM-1 changed significantly (P<0.01 = , but in the treated group, the VEGF increasing surpassed the control group (P<0. 01 = . Post-treatment there was no difference of the level of blood serums sICAM-1 between A group and B group. 3. The syndrome of blood stasis had improved (P<0.01 = , but the treated group got better (P<0.05 = . 4. There was significant positive correlation between the syndrome of blood stasis and sICAM-1 (r = 0.901, P<0.01 =, but the negative correlation with VEGF (r = -0.788, P <0.01).
Conclusion: The levels of VEGF, sICAM-1 had close correlation with the syndrome of blood stasis. Erigeron injection can effectively reduce cerebral ischemic lesions, improve the cerebral blood circulation. It is effective and safe medicine for the acute stage of Cerebral Infarction.
急性脑梗死属于祖国医学“中风”病范畴,其临床表现,大体与现代医学中的急性脑血管病相似。从《内经》开始,后世医家特别强调了瘀血在中风发病中的重要地位。本文认为中风发病的病机核心为气血逆乱,其病变关键为血瘀,而活血化瘀法是治疗中风病的根本大法。本课题在既往相关的研究基础上,进一步探讨血瘀证型急性脑梗死患者的血清VEGF、sICAM-1在治疗前后的变化情况,观察灯盏细辛注射液对于血瘀证型急性脑梗死VEGF、sICAM-1的影响,为临床治疗提供理论的依据。
目的:观察灯盏细辛注射液对于血瘀证型急性脑梗死患者的血管内皮生长因子、可溶性细胞间黏附分子-1、血瘀证积分、神经功能缺损症状的影响,探讨急性脑梗死(ACI)血瘀证与VEGF、sICAM-1的关系,分析灯盏细辛治疗ACI的作用机制,探索脑梗死急性期有效的中医药治疗,为临床治疗提供理论的依据。
方法:将符合选择标准的60例ACI患者随机分为治疗组(A组)和对照组(B组),并设立健康老年人30例为正常对照组(C组),观察病例,分为治疗组(A组)和对照组(B组),各组患者的年龄、性别、既往病史等经统计学处理无显著性差异,具有可比性,A组给予静脉滴注灯盏细辛,B组给予速避凝皮下注射;治疗前后分别检测VEGF、sICAM-1,并对患者的血瘀证积分、神经功能缺损积分等分别做出评定。
结果:1.两组之间的疗效比较,治疗组明显优于对照组(P＜0.05=;2.治疗后两组ACI患者血清VEGF、sICAM-1的含量较治疗前均有显著性改善P＜0.01,但治疗组在治疗后VEGF增高较对照组更为明显P＜0.01;治疗组在治疗后sICAM-1的含量与对照组比较P＞0.05;3.血瘀证积分均较治疗前有显著性改善P＜0.01,但治疗组较对照组改善明显P＜0.05;4.ACI患者血瘀证病情的轻重与sICAM-1含量存在显著正相关r=0.901,P＜0.01;与VEGF呈显著负相关r=-0.788,P＜0.01。
结论:血清VEGF、sICAM-1与ACI血瘀证密切相关;灯盏细辛能改善ACI患者的脑血液循环,减轻脑组织缺血性损伤,是脑梗死急性期安全有效的药物。
Acute cerebral infarction, which is abbreviating ACI, is one of the severe cases in internal medicine. The major pathological basis of ACI is atherosclerosis, which take 80 percents. The angiemphraxis caused ischemic and anoxemia in the corresponding blood supply brain tissue. This formed centre zone of necrosis and ischemia semidarkness lane. Thus to improve the blood supply in the ischemia semidarkness lane is the key point in decreasing the infarct size. At the same time, how to lighten the inflammatory reaction is already one of the important steps in clinical treatment on ischemic cerebrovascular disease. ACI belongs to the stroke in traditional Chinese medicine. ACI is similar to acute cerebrovascular disease in modern medicine. From the endo-meridians on, a large quantity of physicians emphasize the important position of stagnant blood in the pathogenesis of stroke.
This article takes it for granted that the core pathogenesis of the stroke is disharmonizing Qi and blood. The key point of the pathological changes is blood stasis. Thus the treatment method of activating blood circulation to dissipate blood stasis is the basic ones in treating the stroke. This study is based on the former investigation results and to move forward a single step for the variation rule of vascular endothelial growth factor (VEGF) and soluble intercellular adhesion molecule-1 (sICAM-1), in the patients of ACI with the syndrome of blood stasis. Then we observed the affection on VEGF and sICAM-1 in patients of ACI with the syndrome of blood stasis. All the results could provide guideline for clinical treatment on patients with ACI.
Objective: To investigate the changes of Vascular Endothelial Growth Factor (VEGF), Soluble Intercellular Adhesion Molecule-1 (sICAM-1), symptom of neurologic impairment in patients with Acute Cerebral Infarction (ACI) of TCM syndrome of blood stasis with erigeron injection. To analyze the mechanism of erigeron injection on ACI, which provides the indexes for clinical treatment of ACI.
Methods : According to the diagnosis standards and Chinese symptom standards, 60 patients with ACI were randomly divided into treated group (A group) and control group (B group), 30 cases of healthy elders were taken as normal control group (C group).The age, gender and integral of past diseases of all groups had no significant difference by statistic treatment. Patients of A group were treated with erigeron injection through intravenous drip, and the patients in B group used Fraxiparine by subcutaneous injection. The levels of blood serum VEGF, sICAM-1 were respectively measured before and after 14 days' treatment by enzyme- linked immunospecific assay and integral of syndrome of blood stasis and neurologic impairment were measured simultaneously.
Results: 1. Compared the two groups' curative effect, the treatment group obviously surpassed control group (P<0. 05 = . 2. After treatment, the level of blood serums of VEGF, sICAM-1 changed significantly (P<0.01 = , but in the treated group, the VEGF increasing surpassed the control group (P<0. 01 = . Post-treatment there was no difference of the level of blood serums sICAM-1 between A group and B group. 3. The syndrome of blood stasis had improved (P<0.01 = , but the treated group got better (P<0.05 = . 4. There was significant positive correlation between the syndrome of blood stasis and sICAM-1 (r = 0.901, P<0.01 =, but the negative correlation with VEGF (r = -0.788, P <0.01).
Conclusion: The levels of VEGF, sICAM-1 had close correlation with the syndrome of blood stasis. Erigeron injection can effectively reduce cerebral ischemic lesions, improve the cerebral blood circulation. It is effective and safe medicine for the acute stage of Cerebral Infarction.
引文
1.马克夫.血管内皮生长因子与急性脑梗死及实验性治疗[J].国外医学神经病学神经外科分册,2001,28(5):377-379.
2.Memezawa H,Smith MI.Siesijo BK,et al.Penumbral tissues salvaged by reperfusion following middle cerebral artery occlusion in rats[J].Stroke,1992,23:552-559.
3.Baurngaimer I,Piezek A,Manor O,et al.Constitutive expression of phVEGF_(165)after intra muscular gene transfer promotes collateral vessel development in patients with critical limb ischemia[J].Circulation.1998,97:1114-1123.
4.Losordo DW,Vale PR,Syme JF,et al.Gene therapy for myocardial angiogenesis:Initial clinical results With dirct mrocardial injection of phVEGF_(165)as sole therapy for myocardial ischemia[J].Circulation,1998,98(25):2800-2804.
5.Symes JF,Losordo DW,Vak PR,et al.Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease[J].Ann Thorac Surg,1999,68(3):836-837.
6.Couffinhal T,Kelley M,Witaenbichler B,et al.Vascular endothelial growth factor/vascular perneability factor(VEGF/VPF)in normal and atherosclerotic human aneries [J].Am J Pathol,1997,150(5):1673-1685.
7.Pepper MS,Ferrara N,Oci L,et al.Vascular endothelial growth factor(VEGF)induces plasminogen and plasminogen activator inhibitor-1 in microvascular endothelial cells[J].Biocherm Biophys Res Commun.1991,181(2):902-906.
8.Huang J,Ghoudhri TF,Winfree C J,et al.Postisehemie cerebrovascular E-selection expression mediate stissu einjury in murine stroke[J].Stroke,2000,31:3047-3053.
9.Mulvihill NT,Foley JB,Walsh MA,Crean PA.Relationship between intracoronary and peripheral expression of soluble cell adhesion molecules[J].Int J Cardiol,2001,77(23):223-229.
10.Koerig W.inflammation and coronary heart disease,an overview[J].Cardial Rev,2001,9(1);31-35.
11.周华东,陈曼娥,王东.急性脑梗死血清可溶性血管细胞黏附分子的变化及意义[J].中华内科杂志,1997,36:748-750.
12.杨沁清,冷传友,丛日照,等.急性脑梗死患者血浆细胞黏附分子检测及临床意义[J].山东医药,2000,40(13):23-24.
13.吴岩,田凤石,王金良.脑卒中患者血浆细胞黏附分子及其相关因素测定的临床意义[J].河北医药,2002,24(6):455-456.
14.Beech JS,Reckless J,Mosedale DE.Neuroprotection in ischemia reperfusion in jury:an anti-inflammatory approach using a novel broad-spectrum chemokine inhibitor[J].J Cereb Blood Flow Metab,2001,21:683-689.
15.刘昭纯,马月香.关于建立“瘀血生风”概念的思考[J].山东中医杂志,2001,20(1):18.
16.王少阳.中风病血瘀证论治[J].山东中医杂志,1994,13(4):11.
17.任继学.中风病急性期的中医药辨证治疗[J].中国中医急症,1995,(4):2.
18.王建新.中风之本和活血化瘀之用[J].江西中医药,1995,26(4):17.
19.李富汉.略论血瘀与中风[J].国医论坛,2003,18(1):4.
20.张燕.活血化瘀治疗出血性中风小议[J].新疆中医药,2003,2(1):10.
21.Memezawa H,Smith MI.Siesijo BK,et al.Penumbral tissues salvaged by reperfusion following middle cerebral artery occlusion in rats[J].Stroke,1992,23:552-559.
22.Baurngaimer I,Piezek A,Manor O,et al.Constitutive expression of phVEGF_(165)after intra muscular gene transfer promotes collateral vessel development in patients with critical limb ischemia[J].Circulation.1998,97:1114-1123.
23.Losordo DW,Vale PR,Syme JF,et al.Gene therapy for myocardial angiogenesis:Initial clinical results With dirct mrocardial injection of VEGF as sole therapy for myocardial ischemia[J].Circulation,1999,99(30):3800-3803.
24.Symes JF,Losordo DW,Vak PR,et al.Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease[J].Ann Thorac Surg,1999,68(3):836-837.
25.#12 192;205-208.
26.Berleon B,Hauser S,SchollmanC,et al.Differential expression of the two VEGF receptors fit and KDR in placenta and vascular endothelial cells[J].J cell Bioehem,1994.54:56-66.
27.Cystal FG,M,elvaney NG,Rosenfdd MA,et al.Administration of an adenovinus containing the human CFTReDNAO the repirory tract of individual with cyotic fibrosis[J].Nat Gellet.1994,8:42-51.
28.马丽香,李瑞锡.低氧诱导体外培养大鼠星形胶质细胞VEGF的表达[J].解剖学研究,2004,26(3):177-187.
29.Levy AP,Levy NS,Goldberg MA。et al.Post-transcriptional regulation of vascular endothelial growth factor by hypoxia[J].J Biol Chem;1996,271(5):2746-2753.
30.Seko Y,Shinohara T,Mochizuki N,etal.Heart[J]Vessele.1996.11(3):113-122.
31.Kallio PJ,Okaraoto K,O'Brien S。 et al.Signal transduction in hypoxic cells:inducible nuclear tran sloeation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-I alpha[J].EMBO J.1998,17(22):6573-6586.
32.Hugo JH,Bemaudin MM,BellailA,et aL Hypoxia-InducedVascular Endothelial Growth Factor Expression Precedes Neovascularization after Cerebral lschemia [J].American Journal of Pathology.2000,156:965-976.
33.宫萍,刘亢丁,吴江.VEGFR-I,VEGFR-2rnRNA在局灶性脑缺血的表达及作用研究[J].中国老年医学杂志,2002,22:402-403.
34.Takeshita S,Pu LQ,Stein LA,et al.Intramuscular administration of vascular endothelial growth factor induces does-dependent collateral artery augment in a rabbit model of chronic limb ischemia[J].Circulation,1994,90(5pt2):11228-11234.
35.James F,Symes MD.Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease[J].Ann Thorac Surg,1999,68:830-837.
36.Todd K.Fleischer MD-One-month histologic response of transmyocardial laser channels with Clinically significant severecoronary artery disease[J].Circulation, 1999,100:468-474.
37.Hayashi T,Abe K,Itoyama Y.Reduction of isehemic damage by application of vascular endothelial growth faClor in rat brain after transient ischemia[J].J Cereb Blood Flow Metab,1998,18(8):887-895.
38.金伯泉.细胞和分子免疫学[M].第1版.西安:世界图书出版社,1995,34-47.
39.Davies M J,Gordon J L,Hcaring A J,et al.The expression of the adhesion molecules sICAM-1,VCAM-1 in human atherosclerosis[J].Pathol,1993,17(1):223-227.
40.Rothlein R,Mainolfi E A,Czajkowski M.A form of ciculating ICAM-1 in human serum[J].J Immunol,2001,157(8):3788-3793.
41.刘富东,杨倩,储照虎,等.大鼠脑缺血再灌注后ICAM-1的表达与白细胞浸润关系的研究[J].中风与神经疾病杂志,2002,19(2):82-84.
42.张彩玉,刘美萍,刘志挥,等.急性脑梗死血清可溶性细胞问黏附分子的变化及意义[J].中风与神经疾病杂志,2001,18(2):95-96.
43.刘翠萍,李跃林,刘好文,等.老年急性脑梗死患者血清可溶性细胞间黏附分子-1和肿瘤坏死因子-α的变化[J].中华老年医学杂志,2000,19(5):373-374.
44.蔡洪信.sICAM-1与脑缺血再灌注损伤研究进展[J]。中国微循环,2005,9(5):362。
45.金伯泉.细胞和分子免疫学[M].西安:世界图书出版社,1995.34.
46.Davies MJ,Gordon JL,IIcaring AJ,et al.The exprcssion of the adhesion molecules ICAM-1,VCAM-1 in human atherosclerosis[J].Pathol,1993,17(1):223-227.
47.Walpola PL,Gotlieb AI,Cybulsky MI,et al.Expression of ICAM-1 and VCAM-1 and monocyte adherence in arteries exposed to altered shear stress[J].Art Thr Vas Biol,1995,15(1):2-10.
48.林小娟,王海平,刘钦华,等.灯盏细辛注射液对脑梗塞患者血液流变学的影响[J].临床神经病学杂志,2003,16(6):375.
49.罗祖明,商慧芳,席静,等.灯盏花对脑缺血再灌注损伤保护作用的实验研究[J].中风与神经疾病杂志,2001,17(4):230-233.
2.Memezawa H,Smith MI.Siesijo BK,et al.Penumbral tissues salvaged by reperfusion following middle cerebral artery occlusion in rats[J].Stroke,1992,23:552-559.
3.Baurngaimer I,Piezek A,Manor O,et al.Constitutive expression of phVEGF_(165)after intra muscular gene transfer promotes collateral vessel development in patients with critical limb ischemia[J].Circulation.1998,97:1114-1123.
4.Losordo DW,Vale PR,Syme JF,et al.Gene therapy for myocardial angiogenesis:Initial clinical results With dirct mrocardial injection of phVEGF_(165)as sole therapy for myocardial ischemia[J].Circulation,1998,98(25):2800-2804.
5.Symes JF,Losordo DW,Vak PR,et al.Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease[J].Ann Thorac Surg,1999,68(3):836-837.
6.Couffinhal T,Kelley M,Witaenbichler B,et al.Vascular endothelial growth factor/vascular perneability factor(VEGF/VPF)in normal and atherosclerotic human aneries [J].Am J Pathol,1997,150(5):1673-1685.
7.Pepper MS,Ferrara N,Oci L,et al.Vascular endothelial growth factor(VEGF)induces plasminogen and plasminogen activator inhibitor-1 in microvascular endothelial cells[J].Biocherm Biophys Res Commun.1991,181(2):902-906.
8.Huang J,Ghoudhri TF,Winfree C J,et al.Postisehemie cerebrovascular E-selection expression mediate stissu einjury in murine stroke[J].Stroke,2000,31:3047-3053.
9.Mulvihill NT,Foley JB,Walsh MA,Crean PA.Relationship between intracoronary and peripheral expression of soluble cell adhesion molecules[J].Int J Cardiol,2001,77(23):223-229.
10.Koerig W.inflammation and coronary heart disease,an overview[J].Cardial Rev,2001,9(1);31-35.
11.周华东,陈曼娥,王东.急性脑梗死血清可溶性血管细胞黏附分子的变化及意义[J].中华内科杂志,1997,36:748-750.
12.杨沁清,冷传友,丛日照,等.急性脑梗死患者血浆细胞黏附分子检测及临床意义[J].山东医药,2000,40(13):23-24.
13.吴岩,田凤石,王金良.脑卒中患者血浆细胞黏附分子及其相关因素测定的临床意义[J].河北医药,2002,24(6):455-456.
14.Beech JS,Reckless J,Mosedale DE.Neuroprotection in ischemia reperfusion in jury:an anti-inflammatory approach using a novel broad-spectrum chemokine inhibitor[J].J Cereb Blood Flow Metab,2001,21:683-689.
15.刘昭纯,马月香.关于建立“瘀血生风”概念的思考[J].山东中医杂志,2001,20(1):18.
16.王少阳.中风病血瘀证论治[J].山东中医杂志,1994,13(4):11.
17.任继学.中风病急性期的中医药辨证治疗[J].中国中医急症,1995,(4):2.
18.王建新.中风之本和活血化瘀之用[J].江西中医药,1995,26(4):17.
19.李富汉.略论血瘀与中风[J].国医论坛,2003,18(1):4.
20.张燕.活血化瘀治疗出血性中风小议[J].新疆中医药,2003,2(1):10.
21.Memezawa H,Smith MI.Siesijo BK,et al.Penumbral tissues salvaged by reperfusion following middle cerebral artery occlusion in rats[J].Stroke,1992,23:552-559.
22.Baurngaimer I,Piezek A,Manor O,et al.Constitutive expression of phVEGF_(165)after intra muscular gene transfer promotes collateral vessel development in patients with critical limb ischemia[J].Circulation.1998,97:1114-1123.
23.Losordo DW,Vale PR,Syme JF,et al.Gene therapy for myocardial angiogenesis:Initial clinical results With dirct mrocardial injection of VEGF as sole therapy for myocardial ischemia[J].Circulation,1999,99(30):3800-3803.
24.Symes JF,Losordo DW,Vak PR,et al.Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease[J].Ann Thorac Surg,1999,68(3):836-837.
25.#12 192;205-208.
26.Berleon B,Hauser S,SchollmanC,et al.Differential expression of the two VEGF receptors fit and KDR in placenta and vascular endothelial cells[J].J cell Bioehem,1994.54:56-66.
27.Cystal FG,M,elvaney NG,Rosenfdd MA,et al.Administration of an adenovinus containing the human CFTReDNAO the repirory tract of individual with cyotic fibrosis[J].Nat Gellet.1994,8:42-51.
28.马丽香,李瑞锡.低氧诱导体外培养大鼠星形胶质细胞VEGF的表达[J].解剖学研究,2004,26(3):177-187.
29.Levy AP,Levy NS,Goldberg MA。et al.Post-transcriptional regulation of vascular endothelial growth factor by hypoxia[J].J Biol Chem;1996,271(5):2746-2753.
30.Seko Y,Shinohara T,Mochizuki N,etal.Heart[J]Vessele.1996.11(3):113-122.
31.Kallio PJ,Okaraoto K,O'Brien S。 et al.Signal transduction in hypoxic cells:inducible nuclear tran sloeation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-I alpha[J].EMBO J.1998,17(22):6573-6586.
32.Hugo JH,Bemaudin MM,BellailA,et aL Hypoxia-InducedVascular Endothelial Growth Factor Expression Precedes Neovascularization after Cerebral lschemia [J].American Journal of Pathology.2000,156:965-976.
33.宫萍,刘亢丁,吴江.VEGFR-I,VEGFR-2rnRNA在局灶性脑缺血的表达及作用研究[J].中国老年医学杂志,2002,22:402-403.
34.Takeshita S,Pu LQ,Stein LA,et al.Intramuscular administration of vascular endothelial growth factor induces does-dependent collateral artery augment in a rabbit model of chronic limb ischemia[J].Circulation,1994,90(5pt2):11228-11234.
35.James F,Symes MD.Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease[J].Ann Thorac Surg,1999,68:830-837.
36.Todd K.Fleischer MD-One-month histologic response of transmyocardial laser channels with Clinically significant severecoronary artery disease[J].Circulation, 1999,100:468-474.
37.Hayashi T,Abe K,Itoyama Y.Reduction of isehemic damage by application of vascular endothelial growth faClor in rat brain after transient ischemia[J].J Cereb Blood Flow Metab,1998,18(8):887-895.
38.金伯泉.细胞和分子免疫学[M].第1版.西安:世界图书出版社,1995,34-47.
39.Davies M J,Gordon J L,Hcaring A J,et al.The expression of the adhesion molecules sICAM-1,VCAM-1 in human atherosclerosis[J].Pathol,1993,17(1):223-227.
40.Rothlein R,Mainolfi E A,Czajkowski M.A form of ciculating ICAM-1 in human serum[J].J Immunol,2001,157(8):3788-3793.
41.刘富东,杨倩,储照虎,等.大鼠脑缺血再灌注后ICAM-1的表达与白细胞浸润关系的研究[J].中风与神经疾病杂志,2002,19(2):82-84.
42.张彩玉,刘美萍,刘志挥,等.急性脑梗死血清可溶性细胞问黏附分子的变化及意义[J].中风与神经疾病杂志,2001,18(2):95-96.
43.刘翠萍,李跃林,刘好文,等.老年急性脑梗死患者血清可溶性细胞间黏附分子-1和肿瘤坏死因子-α的变化[J].中华老年医学杂志,2000,19(5):373-374.
44.蔡洪信.sICAM-1与脑缺血再灌注损伤研究进展[J]。中国微循环,2005,9(5):362。
45.金伯泉.细胞和分子免疫学[M].西安:世界图书出版社,1995.34.
46.Davies MJ,Gordon JL,IIcaring AJ,et al.The exprcssion of the adhesion molecules ICAM-1,VCAM-1 in human atherosclerosis[J].Pathol,1993,17(1):223-227.
47.Walpola PL,Gotlieb AI,Cybulsky MI,et al.Expression of ICAM-1 and VCAM-1 and monocyte adherence in arteries exposed to altered shear stress[J].Art Thr Vas Biol,1995,15(1):2-10.
48.林小娟,王海平,刘钦华,等.灯盏细辛注射液对脑梗塞患者血液流变学的影响[J].临床神经病学杂志,2003,16(6):375.
49.罗祖明,商慧芳,席静,等.灯盏花对脑缺血再灌注损伤保护作用的实验研究[J].中风与神经疾病杂志,2001,17(4):230-233.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |